- GVP $1.2 billion est. Up 2% year-on-year.
- NSW lamb production reached a new record high.
- Prices were lower for most of the year however recovered strongly by the end of the year.


Production
Lamb slaughter and production
- Lamb production (tonnes, LHS)
- Lamb slaughter ('000 head, RHS)
NSW mutton slaughter was also up strongly to 3.7 million head, an increase of 29% year on year. 18 This was the highest level of mutton slaughter since 2009 and 58% above the 10 year average. 18 Production was also up 30% to 103 thousand tonnes. 18 Overall mutton slaughter and production remains well below the peaks achieved in the 1990’s and early 2000’s which also reflects the changing composition of the national flock.
Price
Sheep Slaughter vs Flock size ('million head)
- Rolling 12 month slaughter (LHS)
- Slaughter 10yr average (LHS)
- Flock size, MLA est (RHS)
- Flock size 10 year average (RHS)
Sheep and lamb prices (cents/kg cwt)
- ESTLI
- NMI
- ESTLI (10 year average)
- NMI (10 year average)
Trade
Sheepmeat exports
Outlook
DPIRD Initiatives in Focus
mRNA vaccine for emergency animal diseases
A pilot project to fast-track emergency animal disease vaccines and help protect the state's livestock industries, has reached a major milestone with an mRNA vaccine successfully manufactured for the first time in NSW.

NSW DPIRD's scientist, Blaine Farrugia, evaluates emergency animal disease vaccines at the Elizabeth Macarthur Agricultural Institute, supporting NSW’s commitment to safeguard livestock from key biosecurity threats. Credit: John Webster NSW DPIRD
The BDV vaccine was manufactured in Sydney by the UNSW RNA Institute after first being developed by US-based biotechnology leader, Tiba Biotech, with input from the Canadian Food Inspection Agency (CFIA), NSW Department of Primary Industries and Regional Development (DPIRD), Queensland Department of Agriculture and Fisheries, Meat & Livestock Australia and the NSW RNA Pilot Facility. The vaccine design was optimised and demonstrated to be efficacious by NSW DPIRD scientists at the Elizabeth Macarthur Agricultural Institute.
While BDV is not an emergency animal disease, the learnings from this successful pilot project are now being applied to the development of vaccines for lumpy skin disease (LSD) and foot-and-mouth disease (FMD), from which Australia remains free.
Economic costs of a large multi-state outbreak of FMD alone have been estimated at more than $80 billion over 10 years Australia-wide, which is why the NSW Government is working with state, territory and national governments and animal industries to safeguard livestock from these key biosecurity threats.
The project team are now investigating whether virus targets identified by the CFIA are suitable for a vaccine against LSD when combined with the novel RNA formulation technology.
All work with exotic viruses is being conducted overseas, while NSW DPIRD scientists at the Elizabeth Macarthur Agricultural Institute work on , demonstrating animal safety and optimising the formulation and dose by evaluating the immune responses of cattle and sheep.
Australian regulatory authorities have very strict standards to demonstrate that the vaccine will be cleared from the animal very rapidly and that there is no safety risk to people.
Work so far indicates that the test LSD mRNA vaccine is quickly metabolised and cleared from the animal.
Biosecurity risks present the most pressing threat to the state’s primary industries sector, with flow-on impacts to our environment and communities.